secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001104659-22-114457
Event type: other_material
Sentiment:  negative
Materiality: 0.72
Item codes: 1.02, 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharmaceuticals terminates setmelanotide license with RareStone for cause over clinical trial breaches
--------------------------------------------------------------------------------

- Terminated exclusive license for setmelanotide in Greater China (China, Hong Kong, Macao) effective Oct 28, 2022.
- Termination for cause: RareStone materially breached obligations to fund and perform key clinical studies including EMANATE trial.
- RareStone objects to termination and says formal response is forthcoming; potential dispute or litigation.
- Agreement originally dated Dec 3, 2021 granted RareStone rights to develop and commercialize setmelanotide in Greater China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465922114457/0001104659-22-114457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465922114457/tm2229621d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer